Genmab

1,356

DKK

+2.57 %

Less than 1K followers

GMAB

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

+2.57%

-17.17%

-9.15%

-8.69%

-15.12%

-34.33%

-42.88%

-0.33%

+3,876.54%

Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.

Market cap

89.76B DKK

Turnover

304.95M DKK

Revenue

21.53B

EBIT %

31.14 %

P/E

11.1

Dividend yield-%

-

Financial calendar

8/5

2025

Interim report Q1'25

7/8

2025

Interim report Q2'25

6/11

2025

Interim report Q3'25

All

Press releases

ShowingAll content types

Regulatory press releaseyesterday

Genmab Announces Initiation of Share Buy-Back Program

Regulatory press release3/22/2025, 3:28 AM

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Press release3/17/2025, 4:19 PM

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release3/12/2025, 6:19 PM

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Regulatory press release3/12/2025, 6:13 PM

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Regulatory press release3/10/2025, 2:13 PM

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Regulatory press release3/4/2025, 4:57 PM

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Regulatory press release2/28/2025, 9:04 PM

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Regulatory press release2/28/2025, 9:00 PM

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Regulatory press release2/25/2025, 7:30 PM

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Press release2/20/2025, 1:00 PM

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Press release2/19/2025, 2:14 PM

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

Regulatory press release2/13/2025, 11:00 AM

Notice to Convene the Annual General Meeting of Genmab A/S

Press release2/12/2025, 6:14 PM

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Regulatory press release2/12/2025, 4:01 PM

Genmab Publishes 2024 Annual Report

Regulatory press release1/23/2025, 8:08 PM

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Regulatory press release1/22/2025, 11:23 AM

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Press release1/3/2025, 6:55 PM

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Press release12/11/2024, 1:20 PM

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Press release12/9/2024, 5:00 PM

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.